Blow For Novartis Eye Drug Beovu As Studies Stop On Safety Worries
Intraocular Inflammation Cases Higher Than Rival
The Swiss giant Novartis has decided to halt the MERLIN, RAVEN and RAPTOR studies of Beovu "in the interests of patient safety" which will make the task of competing with the wet AMD market leader Eylea even tougher.
You may also be interested in...
Entresto and Cosentyx continue to grow but investors will be looking to see if there are candidates in the current portfolio or pipeline that could join them in the mega-blockbuster club.
In this week's podcast edition of Five Must-Know Things: a pioneering KRAS inhibitor approval; Organon’s CEO on the company’s plans; Astellas’s mid-term ambitions; trial disappointment for Novartis’s Beovu; and Indian plans for a pediatric COVID vaccine.
New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.